All About Eye Drops: Warnings To Six Homeopathic And Two Allopathic Firms; Seven US, One Swiss
Executive Summary
Common across warnings is all the firms, retailers as well as manufacturers, are marketing OTC eye drops with noncompliant claims, including “prevent or improve cataracts” and “temporarily alleviate blepharitis symptoms.” One also had GMP problems.
You may also be interested in...
Litigation Follows OTC Eye Drops Recall Due To Bacteria Strain Not Previously Seen In US
Following a recall earlier in February of EzriCare’s and Delsam’s OTC artificial tears due to potential bacterial contamination, plaintiffs’ bar steps in with first of what may be multiple lawsuits. CDC says drug-resistant strain of Pseudomonas aeruginosa bacteria not previously seen in US.
Latest Steps In FDA Homeopathy Policy Overhaul Prompt Trade Group Questions
A revised draft introduces list of risk-based enforcement priorities but doesn't necessarily tighten FDA oversight of homeopathics manufacturing and marketing, say CHPA and AIH.
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.